Andressa Dias Costa, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Pancreatic Ductal | 10 | 2024 | 1728 | 1.140 |
Why?
|
Pancreatic Neoplasms | 12 | 2024 | 5368 | 0.860 |
Why?
|
Tumor Microenvironment | 13 | 2024 | 3878 | 0.720 |
Why?
|
Colorectal Neoplasms | 8 | 2022 | 6938 | 0.370 |
Why?
|
Adenocarcinoma | 2 | 2023 | 6345 | 0.310 |
Why?
|
Neoadjuvant Therapy | 4 | 2024 | 2828 | 0.250 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 1092 | 0.240 |
Why?
|
Deoxycytidine | 2 | 2024 | 877 | 0.220 |
Why?
|
Leucovorin | 1 | 2024 | 643 | 0.210 |
Why?
|
Fusobacterium Infections | 1 | 2021 | 53 | 0.180 |
Why?
|
Paclitaxel | 2 | 2024 | 1732 | 0.170 |
Why?
|
Fusobacterium nucleatum | 1 | 2021 | 179 | 0.170 |
Why?
|
Microsatellite Instability | 2 | 2020 | 716 | 0.170 |
Why?
|
Fluorouracil | 1 | 2024 | 1642 | 0.170 |
Why?
|
Granulocytes | 1 | 2021 | 551 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11742 | 0.160 |
Why?
|
Interleukin-1beta | 1 | 2024 | 999 | 0.160 |
Why?
|
Natural Killer T-Cells | 1 | 2021 | 322 | 0.150 |
Why?
|
Receptor, IGF Type 1 | 1 | 2020 | 380 | 0.150 |
Why?
|
Myeloid Cells | 1 | 2020 | 823 | 0.130 |
Why?
|
Leukocytes | 1 | 2021 | 2026 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 1802 | 0.100 |
Why?
|
Monocytes | 1 | 2021 | 2570 | 0.100 |
Why?
|
Cell Lineage | 1 | 2020 | 2557 | 0.090 |
Why?
|
Immunotherapy | 2 | 2024 | 4652 | 0.090 |
Why?
|
Prognosis | 8 | 2024 | 29629 | 0.090 |
Why?
|
HLA-DR Antigens | 2 | 2021 | 602 | 0.080 |
Why?
|
Fluorescent Antibody Technique | 2 | 2021 | 2467 | 0.070 |
Why?
|
DNA Methylation | 1 | 2020 | 4399 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 9280 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1745 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2021 | 9177 | 0.060 |
Why?
|
Humans | 20 | 2024 | 761596 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2024 | 8554 | 0.050 |
Why?
|
Claudins | 1 | 2023 | 117 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2024 | 6484 | 0.050 |
Why?
|
Albumins | 1 | 2024 | 575 | 0.050 |
Why?
|
Endocrine Cells | 1 | 2020 | 9 | 0.040 |
Why?
|
Hematoxylin | 1 | 2020 | 60 | 0.040 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2020 | 69 | 0.040 |
Why?
|
Exocrine Glands | 1 | 2020 | 46 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4580 | 0.040 |
Why?
|
Phenotype | 3 | 2023 | 16592 | 0.040 |
Why?
|
Middle Aged | 9 | 2024 | 220921 | 0.040 |
Why?
|
Aged | 8 | 2024 | 169310 | 0.040 |
Why?
|
Male | 11 | 2024 | 360846 | 0.040 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2020 | 330 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2020 | 778 | 0.040 |
Why?
|
Obesity | 1 | 2020 | 12947 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2020 | 553 | 0.040 |
Why?
|
Cyclooxygenase 2 | 1 | 2020 | 597 | 0.040 |
Why?
|
Female | 11 | 2024 | 392705 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1784 | 0.030 |
Why?
|
Pancreatectomy | 1 | 2020 | 811 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2020 | 1085 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 899 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 12463 | 0.030 |
Why?
|
NF-kappa B | 1 | 2024 | 2490 | 0.030 |
Why?
|
beta Catenin | 1 | 2020 | 1040 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2547 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1787 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2021 | 2645 | 0.030 |
Why?
|
Pancreas | 1 | 2020 | 1691 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2024 | 4915 | 0.030 |
Why?
|
Incidence | 2 | 2022 | 21355 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2725 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 2201 | 0.030 |
Why?
|
Prospective Studies | 3 | 2021 | 54423 | 0.030 |
Why?
|
Lymphocytes | 1 | 2020 | 2612 | 0.020 |
Why?
|
Population Surveillance | 1 | 2021 | 2598 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2827 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2020 | 6815 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2020 | 2057 | 0.020 |
Why?
|
Genomics | 1 | 2024 | 5821 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9420 | 0.020 |
Why?
|
United States | 3 | 2021 | 72340 | 0.020 |
Why?
|
Mutation | 2 | 2024 | 30053 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10090 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2021 | 11076 | 0.020 |
Why?
|
Signal Transduction | 2 | 2020 | 23447 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2024 | 10194 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5767 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15601 | 0.020 |
Why?
|
Smoking | 1 | 2022 | 9053 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15266 | 0.010 |
Why?
|
Adult | 3 | 2024 | 221210 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2020 | 16990 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13510 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 22174 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18255 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2022 | 39106 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 41495 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2024 | 64685 | 0.010 |
Why?
|
Risk Factors | 1 | 2022 | 74213 | 0.010 |
Why?
|
Mice | 1 | 2020 | 81539 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2020 | 80647 | 0.010 |
Why?
|
Animals | 1 | 2020 | 168475 | 0.000 |
Why?
|